Evaluating Plasma Uracil Concentration in Patients Without DPD Deficiency
By Gabriel Brooks, MD - Last Updated: March 19, 2025Gabriel Brooks, MD, of the Dartmouth Cancer Center, discusses his latest research on the use of plasma uracil concentration as a screening test for DPD deficiency in patients with gastrointestinal cancer.
Advertisement
Dr. Brooks also explains the association between male sex and 5-FU exposure as well as the study’s overall findings regarding toxicity and DPYD genotype in patients without known DPD deficiency.
Advertisement
Related Posts
The panel covers ASPEN-O6 results, excitement around ADCs in late-line HER-2 and Claudin-positive cancers, and more.
The panel considers tislelizumab amid existing PD-1 inhibitors, zolbetuximab for Claudin-positive patients, and more.
The panel covers updates on 1L treatments for metastatic gastric cancer, including the recent approval of tislelizumab.
The panel explores advancements in early-stage esophageal cancer, emphasizing the paradigm shift toward FLOT chemotherapy.
Personalized Care in Gastric and Esophageal Cancers: Biomarkers, Diagnosis, and Treatment Approaches
The panel focuses on the management of gastroesophageal cancers, highlighting differences in presentations across regions.
630 Madison Ave.
Manalapan, NJ 07726
About Column
Contribute Column
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.